328 related articles for article (PubMed ID: 28093620)
41. Checkpoint inhibitor colitis: a new model of inflammatory bowel disease?
Siakavellas SI; Bamias G
Curr Opin Gastroenterol; 2018 Nov; 34(6):377-383. PubMed ID: 30157044
[TBL] [Abstract][Full Text] [Related]
42. [Clinical practice and mechanism of endocrinological adverse events associated with immune checkpoint inhibitors].
Iwama S; Arima H
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):90-94. PubMed ID: 28603206
[TBL] [Abstract][Full Text] [Related]
43. The safety of nivolumab for the treatment of metastatic melanoma.
O'Reilly A; Larkin J
Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
[TBL] [Abstract][Full Text] [Related]
44. Immune Checkpoint Blockade in Cancer Therapy.
Postow MA; Callahan MK; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1974-82. PubMed ID: 25605845
[TBL] [Abstract][Full Text] [Related]
45. [Side effects of Modern Immunotherapy and How to Solve Them in the Clinics].
Lakomý R; Poprach A
Klin Onkol; 2015; 28 Suppl 4():4S103-14. PubMed ID: 26647898
[TBL] [Abstract][Full Text] [Related]
46. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Vétizou M; Pitt JM; Daillère R; Lepage P; Waldschmitt N; Flament C; Rusakiewicz S; Routy B; Roberti MP; Duong CP; Poirier-Colame V; Roux A; Becharef S; Formenti S; Golden E; Cording S; Eberl G; Schlitzer A; Ginhoux F; Mani S; Yamazaki T; Jacquelot N; Enot DP; Bérard M; Nigou J; Opolon P; Eggermont A; Woerther PL; Chachaty E; Chaput N; Robert C; Mateus C; Kroemer G; Raoult D; Boneca IG; Carbonnel F; Chamaillard M; Zitvogel L
Science; 2015 Nov; 350(6264):1079-84. PubMed ID: 26541610
[TBL] [Abstract][Full Text] [Related]
47. Immune check-point in cervical cancer.
De Felice F; Marchetti C; Palaia I; Ostuni R; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Sep; 129():40-43. PubMed ID: 30097236
[TBL] [Abstract][Full Text] [Related]
48. Immune modulation in cancer with antibodies.
Page DB; Postow MA; Callahan MK; Allison JP; Wolchok JD
Annu Rev Med; 2014; 65():185-202. PubMed ID: 24188664
[TBL] [Abstract][Full Text] [Related]
49. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
[TBL] [Abstract][Full Text] [Related]
50. Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists.
Callahan MK; Wolchok JD
Semin Oncol; 2015 Aug; 42(4):573-86. PubMed ID: 26320062
[TBL] [Abstract][Full Text] [Related]
51. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
52. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
Bronstein Y; Ng CS; Hwu P; Hwu WJ
AJR Am J Roentgenol; 2011 Dec; 197(6):W992-W1000. PubMed ID: 22109345
[TBL] [Abstract][Full Text] [Related]
53. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Bergqvist V; Hertervig E; Gedeon P; Kopljar M; Griph H; Kinhult S; Carneiro A; Marsal J
Cancer Immunol Immunother; 2017 May; 66(5):581-592. PubMed ID: 28204866
[TBL] [Abstract][Full Text] [Related]
54. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
55. Identification and management of toxicities from immune checkpoint-blocking drugs.
Teply BA; Lipson EJ
Oncology (Williston Park); 2014 Nov; 28 Suppl 3():30-8. PubMed ID: 25384885
[TBL] [Abstract][Full Text] [Related]
56. Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Carlino MS; Long GV
Clin Cancer Res; 2016 Aug; 22(16):3992-8. PubMed ID: 27340279
[TBL] [Abstract][Full Text] [Related]
57. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Weber J
Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
[TBL] [Abstract][Full Text] [Related]
58. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.
Jain A; Lipson EJ; Sharfman WH; Brant SR; Lazarev MG
World J Gastroenterol; 2017 Mar; 23(11):2023-2028. PubMed ID: 28373768
[TBL] [Abstract][Full Text] [Related]
59. Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
Aya F; Fernández-Martínez A; Gaba L; Victoria I; Tosca M; Carrera C; Prat A; Arance A
Immunotherapy; 2016 Jun; 8(6):687-92. PubMed ID: 27115320
[TBL] [Abstract][Full Text] [Related]
60. Kidney injuries related to ipilimumab.
Izzedine H; Gueutin V; Gharbi C; Mateus C; Robert C; Routier E; Thomas M; Baumelou A; Rouvier P
Invest New Drugs; 2014 Aug; 32(4):769-73. PubMed ID: 24687600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]